MP Biomedicals completes its range of in vitro diagnostic tests for infectious diseases with new immunochromatographic-based qualitative rapid tests.The new diagnostic kits by MP Biomedicals leverage cutting-edge technology to deliver precise results, enabling healthcare professionals a rapid and accurate detection of Helicobacter pylori, Salmonella typhi and Vibrio cholerae serogroups O1 and O139.
Acquired biotech accuses Novartis of letting IL-15 asset ‘wither on the vine’
Novartis is being accused of deliberately stalling the development of an acquired IL-15 asset, costing a smaller biotech up to $940 million in milestone payments